Live Breaking News & Updates on Ji Xing Pharmaceuticals To

Milestone Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical, Regulatory, and Corporate Update
News provided by
Share this article
Share this article
MONTREAL and CHARLOTTE, N.C., May 17, 2021 /PRNewswire/ Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the first quarter ended March 31, 2021 and provided a clinical, regulatory, and corporate update.
We continue to work closely with our existing clinical trial sites, as well as add new sites, to address the impact that the COVID-19 pandemic has had on patient enrollment in the pivotal Phase 3 RAPID trial of etripamil in patients with PSVT. While we are encouraged by recent improvements in enrollment rates, we now expect to report topline data from the RAPID trial in the second half of 2022, said Joseph Oliveto, President ....

United States , Ji Xing , David Pitts , Joseph Oliveto , Bruce Stambler , Montreal Heart Institute , Company On Twitter At Milestonepharma , Prnewswire Milestone Pharmaceuticals Inc , Ji Xing Pharmaceuticals To , Centers For Disease , Milestone Pharmaceuticals Inc , American College Of Cardiology , Piedmont Heart Institute , Drug Administration , Ji Xing Pharmaceuticals , Company Expects To Report Topline Data , Exchange Commission , Milestone Pharmaceuticals , Chief Executive Officer , Exclusive License Agreement , Commercialize Etripamil , Report Topline Data , Pivotal Phase , New Drug Application , Label Safety Study Amended , Include Repeat Dose ,